Breaking News Instant updates and real-time market news.

SRPT

Sarepta

$118.30

3.44 (3.00%)

17:39
01/10/19
01/10
17:39
01/10/19
17:39

Sarepta up over 1% after positive CNBC Fast Money segment

SRPT Sarepta
$118.30

3.44 (3.00%)

01/02/19
JPMS
01/02/19
NO CHANGE
JPMS
Overweight
JPMorgan a buyer of Sarepta into next week's healthcare conference
Both Sarepta Therapeutics (SRPT) and Solid Biosciences (SLDB) have important clinical events in Q1 of 2019, JPMorgan analyst Anupam Rama tells investors in a research note. Preliminary data from Solid's ongoing phase 1/2 IGNITE-DMD trial of SGT-001 micro-dystrophin gene therapy in Duchenne muscular dystrophy are expected in the quarter, the analyst says. He believes these data will have important read-through to the micro-dystrophin space, including Sarepta's program. Further, Sarepta will be presenting 60-day biopsy data from Cohort 1 in early-2019 from the ongoing phase 1/2a MYO-101 beta-sarcoglycan gene therapy program in limb-girdle muscular dystrophy type 2E, adds Rama. The analyst is a buyer of Sarepta into his firm's healthcare conference next week and continues to view Solid as a "show me" story.
01/07/19
RBCM
01/07/19
NO CHANGE
RBCM
Outperform
Sarepta's 'unfounded' weakness a buying opportunity, says RBC Capital
RBC Capital analyst Brian Abrahams believes there has been some confusion coming out of an investor presentation this morning on Sarepta's limb girdle muscular dystrophy data and on the regulatory path for microdystrophin gene therapy. After talking with the company, he believes timelines and prospects for both remain intact, views the weakness as "'unfounded" and would use the pullback today as a buying opportunity. Abrahams maintains an Outperform rating on Sarepta shares.
01/08/19
BARD
01/08/19
NO CHANGE
Target $202
BARD
Outperform
Sarepta selloff following conference presentation unwarranted, says Baird
Baird analyst Brian Skorney admitted Sarepta missed an opportunity to impress with their presentation at the JPMorgan healthcare conference, but he thinks the stock reaction is unwarranted. Microdystrophin timelines look consistent and management remains enthusiastic about LGMD data in Q1 and has not seen any expression data yet, said Skorney. He thinks the data is highly likely to be positive and expects the stock to reverse its course. Skorney reiterated his Outperform rating and $202 price target on Sarepta shares.
01/08/19
GSCO
01/08/19
NO CHANGE
GSCO
Goldman Sachs recommends Sarepta ahead of 'key' Q1 catalyst
Goldman Sachs analyst Salveen Richter said he recommends Sarepta shares ahead of key Q1 catalyst -- the MYO-101 Ph1/2 limb girdle muscular dystrophy 60-day biopsy data. Richter added that Sarepta is positioned for a strong year in 2019, as he looks to execution across multiple fronts, including selective BD to drive the R&D engine, golodirsen US approval around Q3, casimersen dystrophin expression data with a potential filing in the middle of the year, SRP-5051 Ph1 data by year end, and additional gene therapy trial progress. The analyst maintained a Buy rating and $191 price target on Sarepta.

TODAY'S FREE FLY STORIES

TBIO

Translate Bio

$5.53

-0.12 (-2.12%)

07:38
01/22/19
01/22
07:38
01/22/19
07:38
Hot Stocks
Translate Bio announces clinical hold on MRT5201 IND application from FDA »

Translate Bio announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INSY

Insys Therapeutics

$4.42

-0.25 (-5.35%)

07:37
01/22/19
01/22
07:37
01/22/19
07:37
Initiation
Insys Therapeutics initiated  »

Insys Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCM

R1 RCM

$8.32

0.16 (1.96%)

07:37
01/22/19
01/22
07:37
01/22/19
07:37
Initiation
R1 RCM initiated  »

R1 RCM initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INTC

Intel

$49.23

0.76 (1.57%)

07:36
01/22/19
01/22
07:36
01/22/19
07:36
Recommendations
Intel analyst commentary  »

Intel Q4 results should…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 24

    Jan

  • 25

    Feb

  • 25

    Mar

  • 26

    Mar

ONCS

OncoSec

$0.71

0.0134 (1.93%)

07:35
01/22/19
01/22
07:35
01/22/19
07:35
Conference/Events
OncoSec management to meet with Maxim »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

D

Dominion

$68.75

-0.15 (-0.22%)

07:35
01/22/19
01/22
07:35
01/22/19
07:35
Downgrade
Dominion rating change  »

JPMorgan downgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

  • 10

    Feb

UBSH

Union Bankshares

$32.50

0.14 (0.43%)

07:35
01/22/19
01/22
07:35
01/22/19
07:35
Earnings
Union Bankshares reports Q4 ex-items EPS 70c, consensus 68c »

Q4 net charge-offs were…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 11

    Feb

JD

JD.com

$23.25

1.12 (5.06%)

, INTC

Intel

$49.23

0.76 (1.57%)

07:35
01/22/19
01/22
07:35
01/22/19
07:35
Options
Unusual call flow in option market yesterday »

Notable call activity was…

JD

JD.com

$23.25

1.12 (5.06%)

INTC

Intel

$49.23

0.76 (1.57%)

WYNN

Wynn Resorts

$115.19

0.94 (0.82%)

NKE

Nike

$80.45

1.33 (1.68%)

CRON

Cronos Group

$14.89

1.25 (9.16%)

MGM

MGM Resorts

$28.55

0.83 (2.99%)

AUY

Yamana Gold

$2.31

-0.12 (-4.94%)

UAA

Under Armour

$20.50

0.47 (2.35%)

I

Intelsat

$21.15

-1.26 (-5.62%)

APC

Anadarko

$48.68

0.61 (1.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 24

    Jan

  • 06

    Feb

  • 10

    Feb

  • 13

    Feb

  • 21

    Feb

  • 25

    Feb

  • 25

    Mar

  • 26

    Mar

INCY

Incyte

$78.44

-0.22 (-0.28%)

07:34
01/22/19
01/22
07:34
01/22/19
07:34
Hot Stocks
Incyte treats first patient in Phase 3 clinical trial of itacitinib »

Incyte Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

AMBR

Amber Road

$8.45

0.19 (2.30%)

07:34
01/22/19
01/22
07:34
01/22/19
07:34
Hot Stocks
Amber Road confirms receipt of director nominations from Altai Capital »

Amber Road confirmed that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 23

    Jan

  • 11

    Feb

CORV

Correvio

$3.24

0.365 (12.70%)

07:34
01/22/19
01/22
07:34
01/22/19
07:34
Recommendations
Correvio analyst commentary  »

Correvio to unlock…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OBSV

ObsEva

$13.72

0.22 (1.63%)

07:33
01/22/19
01/22
07:33
01/22/19
07:33
Conference/Events
ObsEva management to meet with Leerink »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

TGP

Teekay LNG

$12.80

0.23 (1.83%)

07:33
01/22/19
01/22
07:33
01/22/19
07:33
Upgrade
Teekay LNG rating change  »

Teekay LNG upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CABO

Cable One

$850.40

8.96 (1.06%)

07:32
01/22/19
01/22
07:32
01/22/19
07:32
Upgrade
Cable One rating change  »

Cable One upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BRDCY

Bridgestone

$0.00

(0.00%)

07:32
01/22/19
01/22
07:32
01/22/19
07:32
Downgrade
Bridgestone rating change  »

Bridgestone downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVCN

Neovasc

$0.75

0.0001 (0.01%)

, EW

Edwards Lifesciences

$168.41

9.29 (5.84%)

07:31
01/22/19
01/22
07:31
01/22/19
07:31
Hot Stocks
Neovasc announces dismissal of claim brought by Edwards Lifesciences »

Neovasc (NVCN) announced…

NVCN

Neovasc

$0.75

0.0001 (0.01%)

EW

Edwards Lifesciences

$168.41

9.29 (5.84%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jan

  • 31

    Jan

STT

State Street

07:30
01/22/19
01/22
07:30
01/22/19
07:30
Downgrade
State Street rating change  »

State Street downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WERN

Werner

, KNX

Knight-Swift

$32.69

1.005 (3.17%)

07:30
01/22/19
01/22
07:30
01/22/19
07:30
Recommendations
Werner, Knight-Swift analyst commentary  »

Deutsche Bank names…

WERN

Werner

KNX

Knight-Swift

$32.69

1.005 (3.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Apr

PANW

Palo Alto Networks

$203.29

0.06 (0.03%)

, FTNT

Fortinet

$70.50

-2.1 (-2.89%)

07:30
01/22/19
01/22
07:30
01/22/19
07:30
Upgrade
Palo Alto Networks, Fortinet rating change  »

Palo Alto Networks…

PANW

Palo Alto Networks

$203.29

0.06 (0.03%)

FTNT

Fortinet

$70.50

-2.1 (-2.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 06

    Feb

  • 25

    Feb

AIG

AIG

$44.15

0.86 (1.99%)

07:27
01/22/19
01/22
07:27
01/22/19
07:27
Recommendations
AIG analyst commentary  »

Deutsche Bank closes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMMU

Immunomedics

$13.31

-4.75 (-26.30%)

07:25
01/22/19
01/22
07:25
01/22/19
07:25
Downgrade
Immunomedics rating change  »

Immunomedics downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPRO

GoPro

$4.92

0.015 (0.31%)

07:25
01/22/19
01/22
07:25
01/22/19
07:25
Recommendations
GoPro analyst commentary  »

GoPro still…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

  • 25

    Feb

07:25
01/22/19
01/22
07:25
01/22/19
07:25
General news
FX Update »

FX Update: A generally…

SRNE

Sorrento Therapeutics

$2.30

0.04 (1.77%)

07:23
01/22/19
01/22
07:23
01/22/19
07:23
Hot Stocks
Sorrento Therapeutics announces interim RTX study data »

Sorrento Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LXRX

Lexicon

$5.96

-1.73 (-22.50%)

, SNY

Sanofi

$41.50

-0.54 (-1.28%)

07:23
01/22/19
01/22
07:23
01/22/19
07:23
Recommendations
Lexicon, Sanofi analyst commentary  »

Lexicon price target…

LXRX

Lexicon

$5.96

-1.73 (-22.50%)

SNY

Sanofi

$41.50

-0.54 (-1.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

  • 28

    Jan

  • 11

    Mar

  • 22

    Mar

  • 28

    Apr

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.